EMA Annual Report 2016
Posted on 11/05/2017
The European Medicines Agency has published its 2016 Annual Report. The report focuses on the agency’s key achievements in the areas of medicine evaluation, support to research, development of new treatments and the safety monitoring of medicines in real life.
In 2016, the agency recommended a marketing authorisation for 81 medicines for human use, including 27 new active substances. On the veterinary side, 11 medicines were recommended for approval, including six new active substances. A third of these medicines prevent viral or bacterial infections in food-producing animals.
As a result of the safety monitoring of all medicines marketed in the European Union, the product information for over 300 medicines for human use was updated on the basis of new safety data.
The report highlights some of the agency’s main projects, initiatives and achievements in 2016, and contains interviews with stakeholders and EMA representatives on topics of major interest in the area of medicines and health in 2016:
- Vaccine hesitancy – a threat to public health.
- Creating an agile organisation for the 21st century.
- How to reinforce surveillance of antimicrobial consumption.
The last part of the report provides a large amount of data and figures that illustrate the work of EMA and its impact.
You can access the report on the EMA’s website.
